

SUMMARY OF CLAIMS

Claims 6, 10-12, 15-56, and 58-61 are cancelled. Claims 1-5, 8, 9, 13, 14, and 57 are amended. Claims 1-5 and 7-9, 13, 14, and 57 are pending. Withdrawn claims 31-56 and 58-61 were cancelled without prejudice and Applicants reserve the right to pursue these claims in a later divisional application. Reconsideration is respectfully requested in light of the following remarks.

REMARKS

I. Renumbering of Claims

Examiner noted that claim 25 was missing in the originally filed claims and in the amended claims filed 10/19/2007. Applicants wish to thank the Examiner for re-numbering the claims to correct the omission.

II. Oath/Declaration

Applicants attempted to execute a new declaration, but mail sent to the last known address of inventor Keith Steward was returned. Applicants have continued their attempts to contact the inventor.

III. Specification

A. The Examiner objected to the disclosure for containing an embedded hyperlink and/or other form of browser-executable code in paragraph 0090. Applicants provide a replacement paragraph 0090 that is free of the offending browser-executable code. Hence, Applicants respectfully ask Examiner to withdrawal the objection.

B. The Examiner objected to the informal usage of registered marks in the specification. More specifically, the Examiner noted that the terms BIOSIS, GENBANK AND AFFYMETRIX GENECHIP appear in the specification without all the letters capitalized and without the trademark symbol.

Applicants have searched the specification for informal usage of registered marks and made corrections to the specification where appropriate. Replacement paragraphs 0009, 0010, and 0074, free of informal usage of registered marks, are provided and hence, Applicants request Examiner to withdraw the objection.

IV. Claim Objections

A. Objection of Claim 5 under 35 U.S.C. §1.75

Applicant is advised that should claim 5 be found allowable, claim 6 will be objected to under 37 C.F.R. §1.75 as being a substantial duplicate thereof. Applicants have cancelled claim 6, rendering the objection moot.

B. Objection of Claim 25 for Informality

Claim 25 is objected to on grounds of informality. The objection is now moot as Applicants have cancelled the claim.

V. Claim Rejections

A. Claim Rejections under 35 U.S.C. §112

Claims 1-5, 7-9, 13, 14, and 57 are rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 57

Claims 1 and 57 are rejected for allegedly lacking insufficient antecedent basis for the limitation “each such reaction.” The rejection is now moot as Applicants have deleted the offending term and replaced it with “the disease-related pathway.” Support for this term is found in the claim as originally filed and in claim 1 of Provisional Patent Application 60/353176.

Claim 1

Claim 1 is rejected for allegedly lacking insufficient antecedent basis for the limitation “the stored concepts.” The rejection is now moot as Applicants have deleted the offending term and

replaced it with “the stored genomics information.” Support for this term is found in paragraphs 0066, 0067, and 0073.

Claim 2

Claim 2 is rejected for allegedly lacking sufficient clarity for the use of the term “the proteins that result.” The rejection is now moot as Applicants have deleted the offending term and replaced it with “proteins expressed from said genes” as suggested by Examiner.

Claims 3- 6

Claims 3-6 are rejected for allegedly lacking insufficient antecedent basis for the limitation “the data.” The rejection is now moot as Applicants have deleted the offending term and replaced it with “said genomics information.” Support for this term can be found in paragraphs 0066, 0067, and 0073 and claim 1 as originally filed.

Claims 8 and 9

Claims 8 and 9 are rejected for allegedly lacking clear antecedent basis for the limitation “the candidate drug discovery targets.” The rejection is now moot as Applicants have deleted the word “candidate.” Applicants respectfully contend that the word “candidate” is redundant when used to refer to a drug discovery target as all drug discovery targets are candidates for further development. Support for the deletion of this term can be found in the preamble of claim 1 as originally filed.

Claims 13 and 14

Claims 13 and 14 are rejected for allegedly lacking clear antecedent basis for the limitation “gene product.” The rejection is now moot as Applicants have restated the limitation to be a “protein expressed from said gene.”

Claim 14

Claim 14 is rejected for allegedly lacking clarity as to what relationships would be removed from or how one skilled in the art could determine what specifically comprises the relationships to distinguish them by said step. The rejection is now moot as Applicants have amended claim 14 to state that the method “identifies relationships between genes and/or proteins expressed from said

genes that are at least two steps removed from each other in a disease-related pathway." Support for this term is found in claim 1 as originally filed.

B. Claim Rejections under 35 U.S.C. §101

Claims 1-5, 7, 8, 13, 14, and 57 are rejected under 35 U.S.C. 101 for allegedly being directed to non-statutory subject matter. Applicants traverse the rejection.

Applicants amended independent claims 1 and 57 to include an accessing step, thereby providing a useful, tangible and concrete final result. Support for the claim amendments can be found in the specification as filed. More specifically, paragraph 0066 describes and information system wherein genomics information is accessed. Paragraph 0155 discloses displaying computer-generated graphical displays of the profiles. Furthermore, use of computer generated data necessarily requires the accessing or outputting of results. Therefore, Applicants respectfully request the withdrawal of the rejection of claims 1-5, 7, 8, 13, 14, and 57 under 35 U.S.C. 101.

C. Claim Rejections under 35 U.S.C. §102

In order for Applicant's claims to lack novelty under 35 U.S.C. § 102, each and every element of the claimed invention must be disclosed in a single prior art reference. For a reference to be considered a prior art reference under 35 U.S.C. §102(b), the reference must be published in this or a foreign country more than one year prior to the date of application for patent in the United States.

Claims 1-5, 7, 8, 13, 14, and 57 are rejected under 35 U.S.C. §102(b) over Qu et al.

Claims 1-5, 7, 8, 13, 14, and 57 are rejected under 35 U.S.C. §102(b) as being anticipated by Qu et al. Applicants traverse the rejection.

Applicants respectfully note that Qu et al. was published around April 8, 2002 as evidenced by the date stamp provided by the University of Wisconsin Library. Attached. U.S. Patent Application No. 10/632,099. was filed on August 1, 2003 and claims priority to PCT application PCT/US03/03006 filed on February 3, 2003. The PCT application claims priority to U.S. Provisional Application No. 60/353,176 filed on February 4, 2002. Because Qu et al. was published after the filing date of the '176 application, it is not prior art to any claim entitled to the priority date.

At least claims 1-5, 7, 8, 13, 14, and 57 of the instant application are supported by at least the following disclosures in the provisional application and thereby are entitled to a priority date before Qu et al. was published.

Claim 1

Claim 1 of the instant application, as amended, finds support in bridging paragraph of pages 10 and 11 and in claim 1 of the provisional application.

Claim 2

Claim 2 of the instant application, as amended, finds support in the last full paragraph on page 10, first two full paragraphs on page 11, and claim 2 of the provisional application.

Claim 3

Claim 3 of the instant application, as amended, finds support in the last full paragraph on page 4, first full paragraph on page 10, and claim 3 of the provisional application.

Claim 4

Claim 4 of the instant application, as amended, finds support in the last full paragraph on page 4, first full paragraph on page 10, and claim 4 of the provisional application.

Claim 5

Claim 5 of the instant application, as amended, finds support in the last full paragraph on page 4, first full paragraph on page 10, and claim 5 of the provisional application.

Claim 7

Claim 7 of the instant application, as amended, finds support in the third full paragraph on page 5 to the first full paragraph on page 8, and claim 7 of the provisional application.

Claim 8

Claim 8 of the instant application, as amended, finds support in the first full paragraph on page 11, and claim 4 of the provisional application.

Claim 13

Claim 13 of the instant application, as amended, finds support in the last full paragraph on page 4, last full paragraph on page 10, and claim 9 of the provisional application.

Claim 14

Claim 14 of the instant application, as amended, finds support in the first two paragraphs on page 5, the last full paragraph on page 10 and claim 5 of the provisional application.

Claim 57

Claim 57 of the instant application, as amended, finds support in the last full paragraph on page 10 and the bridging paragraph on pages 10 and 11.

Applicants respectfully assert that at least claims 1-5, 7, 8, 13, 14, and 57 are supported by disclosure in Provisional Application No. 60/353,176. Based on the filing date of the provisional application, Qu et al. cannot be applied as a prior art reference. Therefore, Applicants respectfully request Examiner withdrawal the rejection of claims 1-5, 7, 8, 13, 14, and 57 under 35 U.S.C. §102(b).

D. Claim Rejections under 35 U.S.C. §103

Claims 16, 17 and 28 are rejected under 35 U.S.C. 103(a) over Qu et al. in view of Bura et al.

Claims 16, 17 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Qu et al., as applied to claims 1-5, 7, 8, 13, 14, and 57 above, further in view of Bura et al. The rejection is now moot as Applicants have cancelled claims 16, 17, and 28.

E. Double Patenting

Claims 1-5, 7, 8, 13, and 14 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-25 of copending Application

Response dated May 19, 2008
Application No.: 10/632,099
Reply to Office Action dated November 19, 2007

No. 10/502,420. Applicants are invited to submit a Terminal Disclaimer to overcome the rejection. As this is a provisional rejection, Applicants will address the rejection upon indication of allowable subject matter by the Examiner.

Response dated May 19, 2008
Application No.: 10/632,099
Reply to Office Action dated November 19, 2007

CONCLUSION


Applicants submit that this paper fully addresses the Office Action mailed November 19, 2007. Should the Examiner have any question, the Examiner is encouraged to telephone the undersigned attorney at (650) 565-3895.

The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit account No. 23-2415 (Attorney Docket No.: 27763-705.501) for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: May 19, 2008

By: 
Paul Borchardt, Reg. No. 53,999

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Client No. 021971

IEEE Intelligent Systems


S
IN 5
EL 24
M
ISA

Also in this issue:

Urban search and rescue robots:
from tragedy to technology

Landmine detection
research pushes forward
Semantic Web annotations

PUTTING AI INTO PRACTICE



This resource is also available
on the WWW.
Use MadCat to launch.

Intelligent Systems in Biology II



<http://computer.org/Intelligent>



DEPARTMENTS

2 From the Editor in Chief

Nigel Shadbolt

Working Smarter, Not Harder

4 Intelligencer

Keri Schreiner

Landmine Detection Research Pushes Forward, despite Challenges

11 Perspectives

Marjory Blumenthal

Frontiers at the Interface between Computing and Biology

63 AI in Space

Daniel E. Cooke and Butler P. Hine III

*Virtual Collaborations with the Real:**NASA's New Era in Space Exploration*

70 Trends & Controversies

Steffen Staab

Ontologies' KISSES in Standardization

81 Histories & Futures

Angela Davids

Urban Search and Rescue Robots: From Tragedy to Technology

84 Intelligent Transportation Systems

Shiu Kit Tso, Ka Lun Fan, Yongde Zhang, and Chun Man Chan

An Automated Gas Station Attendant

88 Internet Services

Giovanni Flammia

The Web: A Communication Medium for Health Care

54 Computer Society Membership Info

62 Advertiser Index

Editor in Chief
Nigel Shadbolt
University of Southampton
nrs@ecs.soton.ac.uk

Associate Editor in Chief
Austin Tate
University of Edinburgh
a.tate@ed.ac.uk

EDITORIAL BOARD

Richard Benjamins

Intelligent Software Components

Richard J. Doyle

Jet Propulsion Lab

Douglas Dyer

DARPA

Dieter A. Fensel

Vrije Universiteit Amsterdam

Yolanda Gil

University of Southern California

C. Lee Giles

NEC Research Institute

Kristian I. Hammond

University of Chicago

James V. Hansen

Brigham Young University

James A. Hendler

University of Maryland

Haym Hirsh

Rutgers University

Se-June Hong

IBM T.J. Watson Research Center

Eric Horvitz

Microsoft Research

Craig Knoblock

University of Southern California

Robert Laddaga

Massachusetts Institute of Technology

Richard H. Lathrop

University of California, Irvine

Robin R. Murphy

University of South Florida

Daniel E. O'Leary

University of Southern California

Aun Precece

University of Aberdeen

Paul S. Rosenblom

University of Southern California

Howard E. Shrobe

Massachusetts Institute of Technology

Rudi Studer

University of Karlsruhe

William R. Swartout

University of Southern California

Mark L. Swinson

DARPA

Miltiad Tambe

University of Southern California

David L. Waltz

NEC Research Institute

Ronald Yager

Iona College

CS MAGAZINE OPERATIONS COMMITTEE

Sorit Sircar (chair), James H. Aylen, Jean Bacon, Thomas J. Bergin, Vishwanath Chalapathy, William I. Grusky, Steve McConnell, Koenraad Moens, Venkateswaran Sivarayanan, Nigel Shadbolt, Muniandy P. Singh, Francis Sullivan, James J. Thomas, Yervant Zorian

CS PUBLICATIONS BOARD

Ramgopal Kasturi (vice president), Jean Bacon, Mark Christensen, George Cybenko, Thomas Keefe, Richard A. Kemmerer, Gabriella Sanniti di Baja, Steven L. Tanimoto, Anand Tripathi